This study is designed to evaluate the efficacy and safety in Social Anxiety Disorder (SAD)
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
50
GSK Investigational Site
Saitama, Japan
GSK Investigational Site
Tokyo, Japan
GSK Investigational Site
Change from baseline in the LSAS total score at week 52 (Score at week 52- Score at week 0)
Time frame: 52 Weeks
Proportion of patients responding with a CGI Global Improvement Item. Change from baseline in the CGI Severity of Illness score. Change from baseline in the HAM-D total score. Proportion of patients continuing treatment.
Time frame: 52 Weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.